This SWAP design enables modular targeting of therapeutically relevant receptors to achieve a more favourable receptor-targeting profile with reduced binding to IR-A and IGF1R and novel receptor binding properties, relevant for the clinical translation of lentiviral gene therapies for lysosomal disorders such as Hunter syndrome. The gene discussed is IGF1R; the disease is mucopolysaccharidosis type 2.